- Home
- ROIV vs SPXC Comparison
ROIV vs SPXC Comparison
Compare ROIV & SPXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- SPXC
- Stock Information
- Founded
- ROIV 2014
- SPXC 1912
- Country
- ROIV United Kingdom
- SPXC United States
- Employees
- ROIV N/A
- SPXC N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- SPXC Industrial Machinery/Components
- Sector
- ROIV Health Care
- SPXC Industrials
- Exchange
- ROIV Nasdaq
- SPXC Nasdaq
- Market Cap
- ROIV 8.4B
- SPXC 8.0B
- IPO Year
- ROIV N/A
- SPXC N/A
- Fundamental
- Price
- ROIV $11.91
- SPXC $171.77
- Analyst Decision
- ROIV Strong Buy
- SPXC Hold
- Analyst Count
- ROIV 10
- SPXC 2
- Target Price
- ROIV $17.39
- SPXC $142.00
- AVG Volume (30 Days)
- ROIV 7.9M
- SPXC 212.9K
- Earning Date
- ROIV 11-11-2024
- SPXC 10-30-2024
- Dividend Yield
- ROIV N/A
- SPXC N/A
- EPS Growth
- ROIV N/A
- SPXC 88.76
- EPS
- ROIV 5.65
- SPXC 2.23
- Revenue
- ROIV $158,303,000.00
- SPXC $1,884,600,000.00
- Revenue This Year
- ROIV $53.59
- SPXC $16.99
- Revenue Next Year
- ROIV $26.91
- SPXC $5.35
- P/E Ratio
- ROIV $2.11
- SPXC $77.18
- Revenue Growth
- ROIV 101.44
- SPXC 16.13
- 52 Week Low
- ROIV $8.25
- SPXC $77.84
- 52 Week High
- ROIV $13.06
- SPXC $173.30
- Technical
- Relative Strength Index (RSI)
- ROIV 56.47
- SPXC 70.06
- Support Level
- ROIV $11.71
- SPXC $167.64
- Resistance Level
- ROIV $12.01
- SPXC $173.30
- Average True Range (ATR)
- ROIV 0.24
- SPXC 3.63
- MACD
- ROIV 0.06
- SPXC 0.83
- Stochastic Oscillator
- ROIV 81.91
- SPXC 90.76
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About SPXC SPX Technologies Inc.
SPX Technologies Inc supplies engineered heating, ventilation, and air conditioning, or HVAC, products, as well as detection and measurement technologies and power equipment. The company through two reportable segments. The HVAC segment which generates the majority of the revenue for the company, designs, manufactures, installs, and services cooling products, as well as heating and ventilation products. The detection and measurement technologies segment designs, manufactures, and installs underground pipe and cable locators and inspection equipment, bus-fare collection systems, and others. Geographically, the company generates majority of its revenue in the United States and rest from China, United Kingdom and other regions.